Product Code: SR112024A2871
The global foot and mouth disease (FMD) vaccine market size reached US$ 2,129.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 3,861.8 Million by 2032, exhibiting a growth rate (CAGR) of 6.6% during 2024-2032.
The foot and mouth disease (FMD) occurs due to a transboundary, contagious virus that infects cloven-hoofed animals. It primarily affects cattle, such as buffaloes, pigs, sheep, goats, etc., and a few wildlife species, including deer, bison, camelid, antelope, etc. The FMD virus (FMDV) has seven immunologically distinct serotypes, namely O, A, C, SAT1, SAT2, SAT3, and Asia 1. This viral disease exhibits common symptoms in animals, such as blisters on lips and tongue, fever, excessive salivation, anorexia, low meat and milk productivity, etc. Several vaccines, based on aluminum hydroxide, saponin, and oil formulations, are used against FMD contraction.
The high prevalence of FMD along with its socio-economic impact on the international trade of animal products is driving the FMD vaccine market. The growing meat processing industry and the increasing consumption of dairy products are also fueling the need for FMD vaccines. Additionally, the rising demand for high-grade and disease-free meat supply from livestock is further augmenting the market growth. Apart from this, the implementation of mandatory norms regarding cattle rearing is leading to the bulk purchase of vaccines to control FMD outbreaks. Furthermore, government bodies across the globe are also introducing several awareness programs for protecting endangered wildlife species, such as bison and antelope, against FMD. Rising globalization along with the growing livestock population across both developed and developing markets is also driving the market for FMD vaccines. Furthermore, the increasing presence of veterinary centers providing safe healthcare practices for livestock is also creating a positive impact on the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global foot and mouth disease (FMD) vaccine market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on animal type, vaccine type and distribution channel.
Breakup by Animal Type:
Cattle
Pig
Sheep and Goat
Others
Breakup by Vaccine Type:
Conventional Vaccines
Oil-Based Vaccines
Aluminum hydroxide/saponin-based Vaccines
Emergency Vaccines
Breakup by Distribution Channel:
Government Organizations
Distributors/Pharmacies
Private Vet
Others
Breakup by Region:
Asia Pacific
China
India
Bangladesh
Vietnam
Korea
Others
Latin America
Brazil
Argentina
Others
Middle East and Africa
Nigeria
Ethiopia
Iran
Algeria
Others
Europe
Turkey
Georgia
Armenia
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Paramount Agrovet Pvt. Ltd., Bayer AG, Biogenesis Bago, Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private Limited, China Animal Husbandry Group, FGBI "Federal Center for Animal Health", Indian Immunologicals Ltd., Limor De Colombia, Merck & Co., Inc., Vecol S.A and Vetal Animal Health Products Inc.
Key Questions Answered in This Report:
- How has the global foot and mouth disease (FMD) vaccine market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global foot and mouth disease (FMD) vaccine market?
- What are the key regional markets?
- What is the breakup of the market based on the animal type?
- What is the breakup of the market based on the vaccine type?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global foot and mouth disease (FMD) vaccine market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Foot and Mouth Disease (FMD) Vaccine Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Animal Type
- 6.1 Cattle
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Pig
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Sheep and Goat
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Vaccine Type
- 7.1 Conventional Vaccines
- 7.1.1 Market Trends
- 7.1.2 Oil-Based Vaccines
- 7.1.2.1 Market Trends
- 7.1.2.2 Market Forecast
- 7.1.3 Aluminum hydroxide/saponin-based Vaccines
- 7.1.3.1 Market Trends
- 7.1.3.2 Market Forecast
- 7.1.4 Market Forecast
- 7.2 Emergency Vaccines
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Government Organizations
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Distributors/Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Private Vet
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 Asia Pacific
- 9.1.1 China
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 India
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.3 Bangladesh
- 9.1.3.1 Market Trends
- 9.1.3.2 Market Forecast
- 9.1.4 Vietnam
- 9.1.4.1 Market Trends
- 9.1.4.2 Market Forecast
- 9.1.5 Korea
- 9.1.5.1 Market Trends
- 9.1.5.2 Market Forecast
- 9.1.6 Others
- 9.1.6.1 Market Trends
- 9.1.6.2 Market Forecast
- 9.2 Latin America
- 9.2.1 Brazil
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Argentina
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 Others
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.3 Middle East and Africa
- 9.3.1 Nigeria
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 Ethiopia
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 Iran
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Algeria
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Others
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.4 Europe
- 9.4.1 Turkey
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Georgia
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Armenia
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porter's Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Paramount Agrovet Pvt. Ltd.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Bayer AG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Biogenesis Bago
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Boehringer Ingelheim International GmbH
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Brilliant Bio Pharma Private Limited
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 China Animal Husbandry Group
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 FGBI "Federal Center for Animal Health"
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Indian Immunologicals Ltd.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Limor de Colombia
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 Merck & Co. Inc
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Vecol S.A.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.12 Vetal Animal Health Products Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio